LEPR and metabolic dysfunction-associated steatotic liver disease: Although individual cell experiments provide substantial evidence that metformin is harmful in NAFLD treatment when there is a Lepr defective in the hepatocytes, this is still in need of verification in liver-specific Lepr-KO animals before applying it to clinical settings.